MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

11/01/2013 by Arezu Sarvestani

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Deflating the hype: Are we setting renal denervation up for disappointment?

Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn't curbed much of the hype for the technology as a means of treating patients with...

10/16/2013 by Brian Johnson

CeQur CEO Jim Peterson discusses the motivation behind his mission to improve the lives of patients who suffer from Type II diabetes.

Diabetes: CeQur CEO Jim Peterson's personal mission to improve the standard of care

Most people are brought into the medical device industry because of a passion for a specific disease or a personal connection to a condition that's had an impact on his or her life.

For Jim Peterson, the CEO and founder of CeQur, that motivation was right inside his own house. His daughter was diagnosed...

08/26/2013 by Arezu Sarvestani

The absence of reported hacks on medical devices doesn't mean they aren’t happening, experts say, because there are no mechanisms in place to detect them.

How would we know if medical devices had been hacked?

The FDA has made medical device cybersecurity a high priority, even as it stresses that there have been no reported incidents of malicious medical device hacks or of patients harmed by a security-related issue.

...

08/20/2013 by Sony Salzman

Venaxis CEO Steve Lundy tells MassDevice.com how a rapid blood test to rule out appendicitis can help eliminate unnecessary CT scans in the emergency room.

MassDevice.com Q&A: Venaxis CEO Steve Lundy

Of the 10.5 million cases of abdominal pain that present in American emergency rooms each year, only about 300,000 end up being confirmed as appendicitis. That means an expensive glut of ultimately unnecessary – and potentially cancer-causing – CT scans performed in ERs.

Venaxis CEO Steve Lundy believes his firm's diagnostic test can help eliminate those unnecessary abdominal scans, which use...

08/15/2013 by Arezu Sarvestani

From rampant hack-ability to risk transparency and hospital budgets, Medical Device Innovation, Safety & Security Consortium co-founder and executive director Dr. Dale Nordenberg tells MassDevice.com how a swath of healthcare industry stakeholders are coming together to build tools to address cybersecurity in medical devices.

New tools allow hospitals to compare medical devices based on their cybersecurity

Regulators and healthcare providers are developing tools and standards to assess medical devices and their digital defenses, as medtech cybersecurity takes some giant...

07/30/2013 by Brad Perriello

James Mazzo, the former head of Abbott Medical Optics, tells MassDevice.com about his decision to become Versant Ventures' 1st operating partner.

MassDevice.com Q&A: James Mazzo on his move to Versant Ventures

James Mazzo has put 35 years into the optics and ophthalmology business, so it was no surprise that he got involved with AcuFocus and its device for treating presbyopia. Mazzo, who stepped down from leading Abbott Medical Optics earlier this year, added another title to his resume that's more of a departure: He's the 1st "operating partner" at Versant...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp